Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different-dose polyethylene glycol loxenatide in obese adults with type 2 diabetes
ChiCTR2200056789Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Feb 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: Fasting blood glucose, 2-hour postprandial blood glucose and 14 more. Started Feb 2022; status: recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR2200056789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056789.